Mayo Clinic Study: Drug Combination Shows Promise in Combating Diabetic Kidney Disease
Researchers at the Mayo Clinic have identified a combination therapy—the cancer drug dasatinib and the naturally occurring substance quercetin—that may reduce the damaging effects of “zombie cells,” or senescent cells, in patients with diabetic kidney disease. The findings, published in eBioMedicine, suggest a potential fresh approach to treating this debilitating condition.
The Problem: Diabetic Kidney Disease and Senescent Cells
Diabetic kidney disease (DKD) affects over 12 million people in the United States and is a leading cause of kidney failure [1]. While existing treatments can slow the progression of kidney dysfunction, a cure remains elusive.
A key factor in the development and progression of DKD is the accumulation of senescent cells. These cells, which have stopped dividing but don’t die, release harmful substances that contribute to inflammation and tissue damage [2]. Researchers are increasingly focused on targeting these cells as a potential therapeutic strategy.
Senolytics: A New Approach to Treatment
Senolytics are a class of drugs designed to selectively eliminate senescent cells. The combination of dasatinib and quercetin has emerged as a promising senolytic agent. In a previous pilot clinical trial, Mayo Clinic researchers found that dasatinib and quercetin reduced senescent cells in skin and fat tissues of patients with DKD [1].
Study Findings: Improved Kidney Function and Reduced Inflammation
The recent study, conducted in a preclinical model of DKD, demonstrated that the dasatinib-quercetin combination improved kidney function and reduced markers of kidney injury, fibrosis, and inflammation [2]. Specifically, the therapy reduced the abundance of senescent cells (measured by p16Ink4a levels) and decreased inflammation within the kidneys.
the treatment increased levels of geroprotective factors, such as α-Klotho and Sirtuin-1, which are associated with cellular health and longevity [2]. In vitro studies using human kidney cells confirmed that the combination therapy reduced senescence and inflammation.
What This Means for Patients
“Our study found that the combination therapy, given over a short period of time, reduced the abundance of senescent cells in a preclinical model of diabetic kidney disease and also improved kidney function,” explained LaTonya Hickson, MD, the study’s principal investigator and a nephrologist at Mayo Clinic [1].
Dr. Hickson added that the results suggest larger-scale studies using senolytics should be pursued to improve kidney health in patients with diabetes [1].
Future Research
While these findings are promising, further research is needed to confirm the efficacy and safety of dasatinib and quercetin in humans with DKD. Clinical trials are necessary to determine the optimal dosage, duration of treatment, and potential side effects.